{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T19:23:54Z","timestamp":1793129034530,"version":"4.5.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,16]],"date-time":"2020-11-16T00:00:00Z","timestamp":1605484800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,11,16]],"date-time":"2020-11-16T00:00:00Z","timestamp":1605484800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["19fk0210020h0003"],"award-info":[{"award-number":["19fk0210020h0003"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin J Gastroenterol"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1007\/s12328-020-01287-1","type":"journal-article","created":{"date-parts":[[2020,11,16]],"date-time":"2020-11-16T20:13:32Z","timestamp":1605557612000},"page":"283-287","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["A case with life-threatening secondary sclerosing cholangitis caused by nivolumab"],"prefix":"10.1007","volume":"14","author":[{"given":"Yuki","family":"Yoshikawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michio","family":"Imamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Yamaoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumi","family":"Kosaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eisuke","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Morio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hatsue","family":"Fujino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Nakahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masami","family":"Yamauchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomokazu","family":"Kawaoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masataka","family":"Tsuge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Hiramatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clair Nelson","family":"Hayes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Aikata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunori","family":"Fujitaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kouji","family":"Arihiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noboru","family":"Hattori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4123-6290","authenticated-orcid":false,"given":"Kazuaki","family":"Chayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,16]]},"reference":[{"key":"1287_CR1","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","volume":"54","author":"JM Michot","year":"2016","unstructured":"Michot JM, Bigenwald C, Champiat S, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer. 2016;54:139\u201348.","journal-title":"Eur J Cancer"},{"key":"1287_CR2","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1001\/jamaoncol.2016.1051","volume":"2","author":"CF Friedman","year":"2016","unstructured":"Friedman CF, Proverbs-Singh TA, Postow MA. Treatment of the immune-related adverse effects of immune checkpoint inhibitors: A review. JAMA Oncol. 2016;2:1346\u201353.","journal-title":"JAMA Oncol"},{"issue":"12","key":"1287_CR3","doi-asserted-by":"publisher","first-page":"4585","DOI":"10.2147\/CMAR.S247554","volume":"16","author":"K Shimozaki","year":"2020","unstructured":"Shimozaki K, Sukawa Y, Beppu N, et al. Multiple immune-related adverse events and anti-tumor efficacy: real-world data on various solid tumors. Cancer Manag Res. 2020;16(12):4585\u201393.","journal-title":"Cancer Manag Res"},{"key":"1287_CR4","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD. Immune-Related Adverse Events Associated with Immune Checkpoint Blockade. N Engl J Med. 2018;378:158\u201368.","journal-title":"N Engl J Med"},{"key":"1287_CR5","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/hep.31227","volume":"72","author":"TB Peeraphatdit","year":"2020","unstructured":"Peeraphatdit TB, Wang J, Odenwald MA, et al. Hepatotoxicity from immune checkpoint inhibitors: A systematic review and management recommendation. Hepatology. 2020;72:315\u201329.","journal-title":"Hepatology"},{"key":"1287_CR6","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373:23\u201334.","journal-title":"N Engl J Med"},{"key":"1287_CR7","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372:2521\u201332.","journal-title":"N Engl J Med"},{"key":"1287_CR8","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.15041","author":"T Kitagataya","year":"2020","unstructured":"Kitagataya T, Suda G, Nagashima K, et al. Prevalence, clinical course, and predictive factors of immune checkpoint inhibitor monotherapy-associated hepatitis in Japan. J Gastroenterol Hepatol. 2020. https:\/\/doi.org\/10.1111\/jgh.15041.","journal-title":"J Gastroenterol Hepatol."},{"key":"1287_CR9","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.jemermed.2018.07.005","volume":"55","author":"AT Hryniewicki","year":"2018","unstructured":"Hryniewicki AT, Wang C, Shatsky RA, et al. Management of immune checkpoint inhibitor toxicities: A review and clinical guideline for Emergency Physicians. J Emerg Med. 2018;55:489\u2013502.","journal-title":"J Emerg Med"},{"key":"1287_CR10","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s10637-017-0453-0","volume":"35","author":"H Kawakami","year":"2017","unstructured":"Kawakami H, Tanizaki J, Tanaka K, et al. Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer. Invest New Drugs. 2017;35:529\u201336.","journal-title":"Invest New Drugs"},{"key":"1287_CR11","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s00262-017-2062-3","volume":"67","author":"J Kashima","year":"2018","unstructured":"Kashima J, Okuma Y, Shimizuguchi R, et al. Bile duct obstruction in a patient treated with nivolumab as second-line chemotherapy for advanced non-small-cell lung cancer: a case report. Cancer Immunol Immunother. 2018;67:61\u20135.","journal-title":"Cancer Immunol Immunother"},{"key":"1287_CR12","doi-asserted-by":"publisher","first-page":"e34","DOI":"10.1016\/j.jtho.2017.10.007","volume":"13","author":"JH Cho","year":"2018","unstructured":"Cho JH, Sun JM, Lee SH, et al. Late-onset cholecystitis with cholangitis after avelumab treatment in non-small cell lung cancer. J Thorac Oncol. 2018;13:e34\u20136.","journal-title":"J Thorac Oncol"},{"key":"1287_CR13","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1002\/hep.30189","volume":"69","author":"K Ogawa","year":"2019","unstructured":"Ogawa K, Kamimura K, Terai S. Antiprogrammed cell death-1 immunotherapy-related secondary sclerosing cholangitis. Hepatology. 2019;69:914\u20136.","journal-title":"Hepatology"},{"key":"1287_CR14","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1111\/hepr.13329","volume":"49","author":"Y Koya","year":"2019","unstructured":"Koya Y, Shibata M, Shinohara N, et al. Secondary sclerosing cholangitis with hemobilia induced by pembrolizumab; Case report and review of published work. Hepatol Res. 2019;49:950\u20136.","journal-title":"Hepatol Res"},{"key":"1287_CR15","doi-asserted-by":"publisher","first-page":"353","DOI":"10.3748\/wjg.v26.i3.353","volume":"26","author":"T Onoyama","year":"2020","unstructured":"Onoyama T, Takeda Y, Yamashita T, et al. Programmed cell death-1 inhibitor-related sclerosing cholangitis: a systematic review. World J Gastroenterol. 2020;26:353\u201365.","journal-title":"World J Gastroenterol"},{"key":"1287_CR16","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.2169\/internalmedicine.1981-18","volume":"58","author":"M Kono","year":"2019","unstructured":"Kono M, Sakurai T, Okamoto K, et al. Efficacy and safety of chemotherapy following anti-PD-1 antibody therapy for gastric cancer: a case of sclerosing cholangitis. Intern Med. 2019;58:1263\u20136.","journal-title":"Intern Med"},{"key":"1287_CR17","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s00262-017-2062-3","volume":"67","author":"J Kashima","year":"2018","unstructured":"Kashima J, Okuma Y, Shimizuguchi R, Chiba K. Bile duct obstruction in a patient treated with nivolumab as second-line chemotherapy for advanced non-small-cell lung cancer: a case report. Cancer Immunol Immunother. 2018;67:61\u20135.","journal-title":"Cancer Immunol Immunother"},{"key":"1287_CR18","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1002\/hep.21405","volume":"44","author":"R Abdalian","year":"2006","unstructured":"Abdalian R, Heathcote EJ. Sclerosing cholangitis: a focus on secondary causes. Hepatology. 2006;44:1063\u201374.","journal-title":"Hepatology"},{"issue":"2019","key":"1287_CR19","doi-asserted-by":"publisher","first-page":"6391712","DOI":"10.1155\/2019\/6391712","volume":"17","author":"K Imoto","year":"2019","unstructured":"Imoto K, Kohjima M, Hioki T, et al. Clinical features of liver injury induced by immune checkpoint inhibitors in Japanese patients. Can J Gastroenterol Hepatol. 2019;17(2019):6391712. https:\/\/doi.org\/10.1155\/2019\/6391712.","journal-title":"Can J Gastroenterol Hepatol"},{"key":"1287_CR20","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1093\/annonc\/mdx225","volume":"28","author":"JBAG Haanen","year":"2017","unstructured":"Haanen JBAG, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:119\u201342.","journal-title":"Ann Oncol"},{"key":"1287_CR21","doi-asserted-by":"publisher","first-page":"e59125","DOI":"10.1172\/jci.insight.59125","volume":"3","author":"A Osa","year":"2018","unstructured":"Osa A, Uenami T, Koyama S, et al. Clinical implications of monitoring nivolumab immunokinetics in non-small cell lung cancer patients. JCI Insight. 2018;3:e59125.","journal-title":"JCI Insight"}],"container-title":["Clinical Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-020-01287-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12328-020-01287-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-020-01287-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,19]],"date-time":"2021-02-19T00:33:11Z","timestamp":1613694791000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12328-020-01287-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,16]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["1287"],"URL":"https:\/\/doi.org\/10.1007\/s12328-020-01287-1","relation":{},"ISSN":["1865-7257","1865-7265"],"issn-type":[{"value":"1865-7257","type":"print"},{"value":"1865-7265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,16]]},"assertion":[{"value":"16 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Michio Imamura has received research funding from Bristol-Myers Squibb and AbbVie. Hiroshi Aikata has received honoraria from Eisai and Bayer. Kazuaki Chayama has received honoraria from Bristol-Myers Squibb and MSD K.K., AbbVie, Gilead Science, Dainippon Sumitomo Pharma and Mitsubishi Tanabe Pharma and research funding from\u00a0Gilead Science, Dainippon Sumitomo Pharma, MSD K.K., AbbVie, Eisai, TORAY, Otsuka Pharma, Chugai Pharma, Takeda Pharma and Roche.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures followed have been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human rights"}},{"value":"Informed consent was obtained from all patients for being included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}